



An Investigation on the Antifungal Sensitivity of Candida Isolates in Hospitalized Patients

¹ *Hitesh Bhatt*, ² *Prof. Dr Rohit Kumar*

¹Research Scholar, Malwanchal University

²Research Supervisor Malwanchal University

Introduction

Despite popular belief, *Candida albicans* is not the most common yeast found in Western nations. *Candida* spp. that are not *albicans* may emerge from the selection of more resistant species such as *Candida glabrata* and *C. krusei*. *Candida krusei*, unlike *Candida glabrata*, is inherently resistant to fluconazole. Because *C. tropicalis* attaches to inanimate items such as urine and vascular catheters, antifungal drugs are less effective against it. *C. tropicalis* and *C. albicans* are becoming more resistant to azoles. Because of this, it is very important to have quick methods for identifying species that can find fluconazole susceptibility and point to early treatment options. As a result, we conducted this study to determine the antifungal susceptibility of *Candida* species isolated from hospitalised patients' urine and associated risk factors. The rapid speciation method was compared to standard sugar fermentation processes. increased vaginal glycogen levels, providing *Candida* with an extra carbon source It has been shown that reproductive hormone receptors or systems help *Candida* and yeast cytosol cells stick to vaginal epithelial cells. Many patients on long-term catheterization are asymptomatic and so are unable to express symptoms of increased frequency or dysuria. Those aged 35–40 and 40–45 were the most likely to have no symptoms. Antibiotics were given to 25 of the 50 patients with asymptomatic candidiasis, and another 25 were catheterized as a precaution. Mauricio Mathew et al. (2011) discovered that only 17% of participants showed symptoms of a UTI. UTI symptoms were more prevalent in males over 50 in this research, with 26% having symptomatic candiduria. The rise in risk factors among the elderly may have contributed to the rise.

Methodology

According to this study, 29% of patients were unconscious, needing a lengthier catheterization. They were unable to be characterised as symptomatic or not. Around 15 people were seriously ill in the intensive care unit (ICU), 7 in neurosurgery, and 11 in medicine. This patient group was associated with catheterization and long-term antibiotic therapy. In 15% of instances, fever was the primary symptom, while in 17% of cases, dysuria was the primary symptom. Fever and dysuria were detected in 16.6% and 8%, respectively, of catheterized UTI patients. The Paul A. Tet al study only included participants with candiduria. Catheterization prevents polluted urine from infecting the urethral mucosa and causes symptoms such as dysuria and urgency in patients who are not catheterized. A patent urinary catheter keeps the urinary system decompressed if you have an irritable bladder or vesicoureteral reflux. There were five cases of pyelonephritis, eight cases of cystitis, and 22 cases of UTI. In our study, 18% of nephrology patients participated.

Results

The most prevalent risk factors among medical ward patients were CKD, UTI, and diabetes. In ICU and surgical patients, the most prevalent risk factors were antibiotics and catheterization. Antibiotics were utilised in 84% of cases, while catheters were used in 75%. Uma Chaudary et al. included severely ill patients with candiduria in their analysis, as opposed to the 99.6% of our patients who had catheterization as a risk factor. Antibiotics change the microbiota of the genito-urinary tract, allowing *Candida* species to thrive. Catheters also aid in the colonisation of non-*albicans* *Candida* microbes on their surfaces. The p value for the association between nonalbican *Candida* spp. and antibiotic usage was 0.611. Diabetes (with 42% of the votes) and chronic kidney disease (CKD, with 37% of the votes) came in second and third, respectively. Claudia CB et al. report a little higher (21.8%) diabetes incidence than this research (21.8%). India is renowned as the "Diabetes Capital of the World." Indians have greater insulin resistance, abdominal obesity, lower adiponectin levels, and higher C-reactive protein levels. According to the International Diabetes Federation's Diabetes Atlas 2007, the number of diabetics will rise from 41.8 million in 2007 to 70.1 million by 2025. Steroids (both oral and injectable), tacrolimus, and mycophenolate mofetil are among these medications. These drugs were used to treat SLE, RPGN, and other autoimmune diseases. Another risk factor was that the majority of the patients were on long-term catheters and antibiotics. With a "p" value of 0.003, a Chi-Square test showed that transplantation was a major risk factor for *C. tropicalis* candiduria. 35% of UTIs were caused by chronic kidney disease (CKD). Only 17% of patients in Stephen P S's research exhibited renal insufficiency, compared to 18% in Krcmery S et al. This was most likely attributable to the fact that 50 of every 100 patients were diabetic. Because of their glycosuria and insufficient phagocytes, these people colonise easily. Uremia and hemodialysis increase the risk of infection in people with chronic kidney disease (CKD). Immune system dysfunction, iron overload, underlying illnesses, inadequate albumin, and metabolic acidosis all contribute to it. In those with

chronic renal disease, there was no difference between *Candida albicans* and *Candida nonalbicans* *Candida* species ($p = 0.371$). 15% of the people who were looked into had candiduria because of other kidney problems like calculi, BPH, neurogenic bladder, RPGN, hypospadiasis, phimosis, and prostate cancer. Catheterized urine samples made up 74% of all samples, whereas midstream urine samples were collected from 28% of patients. Patients were catheterized in 81.5 percent of Claudio CB, Artiaga K et al, and Arlene O.C et al studies, which is a typical risk factor. Other *Candida* species accounted for 86.7 percent of the isolates, while *C. albicans* accounted for 14.4%. Non-*Albican* *Candida* species were found in 72.5 percent of the urine isolates examined by Manisha Jain et al. The species population was dominated by *C. tropicalis* (62.25%), followed by *C. albicans* (14.2%), *C. guilliermondii* and *C. krusei* (8.1%), *C. parapsilosis* (5.7%), and *C. kefyr* (5.7%). (1.7 percent). Similar findings were made by Manisha J et al. Her study discovered 56.1% *C. tropicalis* isolates and 29.8% *C. albicans*. Elza H.D. Silva et al. and Febre N et al. identified *C. albicans* as the dominant species, accounting for 46 and 48.17 percent, respectively. More non-*albicans* *Candida* spp. were discovered in these studies. A single isolate was found in more than 99 percent of the 98 urine samples tested. This was consistent with Agarwal's findings. Set a time and date. *C. krusei* was the most prevalent combination isolate, followed by *C. tropicalis*. In reality, the more resilient *C. krusei* was most likely pushing out the original species in the region. *Candida* spp. was discovered in both catheterized and non-catheterized urine samples. A 'p' value of 0.005 was also found between non-*Albican* *Candida* species and catheterized individuals. Fungus causes 27.2 percent of catheter-associated infections. *C. tropicalis*' ability to build catheter biofilms may enhance colonisation in urological draining catheter users. Because of the vast hexosamine-rich matrix of *C. tropicalis* biofilms, antifungal drugs could not enter them, whereas *C. albicans* biofilms possessed a smaller, glucose-rich matrix. It is unknown why non-*albicans* *Candida* spp. have proliferated. It was found in just 6.8% of catheterized individuals and 35.7% of midstream samples. When compared to catheter-free individuals, catheterized patients had a 0.05 p value for *C. albicans* in midstream urine samples. The best strategy for *Candida* speciation was assimilation, which detected 99.9% of *Candida* species. The species identification efficiency of Hi-Chrom agar ranges from 84.3% to 99.9%. Despite a 'p' value of 0.482, the sensitivity of Hi-Chrom agar varied between species, making accurate positive isolate identification challenging. All three *C. parapsilosis* species were 99 percent sensitive, with the exception of *C. tropicalis* (84.3%) and *C. guilliermondii* (84.9%). Chromagar had an 86.7 percent sensitivity. Various *Candida* species are 87–100% Hi-Chrom agar sensitive, according to Chaudary et al. The greater sensitivity of Hi-Chrom agar in our investigation compared to Baradhkar VP et al. might be attributed to the large number of *C. tropicalis* isolates examined. These species showed 100% specificity on Hi-Chrom Agar; *C. albicans* had 95.7 percent specificity, and *C. tropicalis* had 96.2 percent specificity. *Clostridium albicans* had a 97.5 percent specificity, *Clostridium tropicalis* had a 92% specificity, and *Clostridium parapsilosis* had an 88% specificity. Our results are different from those of other studies because we looked at a large number of *C. parapsilosis* isolates. Vivid green colonies only detect *C. albicans* 67% of the time due to the significant number of false positives. Steel blue correctly identified *C. tropicalis* 94.8 percent of the time. Cream, dry pink colonies, and pale pink to purple were predictors for *C. parapsilosis*, *C. krusei*, and *C. guilliermondii*. In this study, fluconazole resistance was found in 23.5% of the *C. tropicalis* isolates and 18.2% of the *C. albicans* isolates. As a result, Ariane Bruder-Nascimento et al. discovered resistance in 17.2% of *C. tropicalis* strains and 24% of *C. albicans* strains. *C. albicans*, on the other hand, was reported to be very sensitive by Ariane BN et al. 3.8% of SDD isolates were sensitive or insensitive due to small DD/MBD differences. In their study, Barry A. L. et al. report an error rate of 8.1%. Only 76.9% of MBD isolates and 70.5% of DD isolates were resistant to itraconazole. These two species were more resistant to itraconazole than the rest. Although 75.4 percent of Ariane B.N et al.'s samples were sensitive, their results are equivalent. MBD and DD incompatibilities resulted in a 12.5 percent minor error and a 1.9 percent major error. Itraconazole responded well to the MBD approach. A 14.1% error in DD suggested that only 86.4% of the isolates were sensitive, but MBD indicated that all were. MBD is the only test that can assess amphotericin B susceptibility. Similar phenomena were identified by Ariane BN and her colleagues.

References

1. Achkar JM, Fries BC. Candidal infections of the genitourinary tract. *Clin Microbiol Rev.* 2010;23:253–273. doi: 10.1128/CMR.00076-09.
2. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. *Candida* species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. *J Med Microbiol.* 2013;62:10–24. doi: 10.1099/jmm.0.045054-0.
3. Gullo A. Invasive fungal infections: the challenge continues. *Drugs.* 2009;69(Suppl 1):65–73. doi: 10.2165/11315530-000000000-00000.
4. Yang YL, Cheng HH, Ho YA, Hsiao CF, Lo HJ. Fluconazole resistance rate of *Candida* species from different regions and hospital types in Taiwan. *J Microbiol Immunol Infect.* 2003;36:187–191
5. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC. Efflux mediated antifungal drug resistance. *Clin Microbiol Rev.* 2009;22:291–321. doi: 10.1128/CMR.00051-08.
6. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. *Clin Microbiol Rev.* 1998;11:382–402.
7. Hospenthal DR, Beckius ML, Floyd KL, Horvath LL, Murray CK. Presumptive identification of *Candida* species other than *C. albicans*, *C. krusei*, and *C. tropicalis* with the chromogenic medium CHROMagar *Candida*. *Ann Clin Microbiol Antimicrob.* 2006;5:1. doi: 10.1186/1476-0711-5-1.
8. Isenberg HD. Mycology and Antifungal Susceptibility Testing. In: Gracia LS, Isenberg HD, editors. *Clinical microbiology procedure handbook*. 2. Washington, DC: ASM Press; 2004. pp. 8.0.1–8.10.7.
9. Kauffman C, Fisher J. *Candida* urinary tract infections: diagnosis. *Clin Infect Dis.* 2011;52(suppl 6):S452–S456. doi: 10.1093/cid/cir111.
10. Yucesoy M, Esen N, Yulung N. Use of chromogenic agar for the identification of *Candida albicans* strains. *Kobe J Med Sci.* 2001;47:161–167.